Zone 1 lidocaine cream recalled because stability data does not support expiry
HTO Nevada, trading as Kirkman, is recalling one lot of Maximum Zone 1 4% Lidocaine Cream because the stability data does not support the labeled expiry date.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Rubric level 2 covers minor labelling errors: the fault is an expiry date the stability data does not support, and the source describes no hazard, illness or injury.
Plain-English summary
HTO Nevada Inc., trading as Kirkman, is recalling MAXIMUM ZONE 1 4% Lidocaine Cream in 1/2 oz bottles, distributed by Dermal Source of Portland, Oregon, NDC 80069-014. About 178 bottles were distributed nationwide within the United States. The FDA has classified this recall as Class II.
The recall was initiated because the stability data does not support the expiry date. The source record does not describe a specific hazard, illness or injury.
Affected product is lot 807CP-0003 with an expiry date of 07/31/2026.
Users can identify affected product by the NDC and lot number above, and may contact HTO Nevada Inc. for further information.
The recalled product
- Product
- MAXIMUM, ZONE 1, 4% Lidocaine Cream, 1/2 oz bottles, Distributed By: Dermal Source, Portland, OR 97232, NDC 80069-014.
- Manufacturer
- HTO Nevada Inc. dba Kirkman
- Category
- Drug — Topical anaesthetic
- Affected units
- 178
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 807CP-0003
- Exp. Date 07/31/2026.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by HTO Nevada Inc. dba Kirkman under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · HTO Nevada Inc. dba Kirkman
See all →- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateDietary Supplement Labeling Error: Kirkman 5-MTHF Folic Acid Misdeclared
FDA (Food) · 2024-05-15
Same hazard · stability failure
See all →- ModerateSafecor Health Recalls Fluphenazine HCl Elixir Due to Stability Failures
FDA (Drugs) · 2026-09-23
- ModerateSafecor Health Recalls Fluphenazine HCl Elixir Due to Stability Failures
FDA (Drugs) · 2026-09-23
- ModerateSafecor Health Recalls Fluphenazine HCl Elixir Due to Stability Failures
FDA (Drugs) · 2026-09-23
- ModerateSafecor Health Recalls Fluphenazine HCl Elixir Due to Stability Failures
FDA (Drugs) · 2026-09-23
- ModerateSafecor Health Recalls Fluphenazine HCl Elixir Due to Stability Failures
FDA (Drugs) · 2026-09-23
Similar recalls
- ModerateLidocaine-Prilocaine Cream Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- SevereRXQ Compounding Recalls Lidocaine Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- ModerateLido E.R. Lidocaine Cream Recalled for Manufacturing Violations
FDA (Drugs) · 2019-07-31
- SevereSoothing Sore Relief Lidocaine Cream Recalled for High Potency
FDA (Drugs) · 2019-09-25
- HighFDA Recalls Maximum Zone2 Topical Analgesic Due to Epinephrine Discoloration
FDA (Drugs) · 2023-02-22
- ModerateLidocaine Cream 4% Recalled Due to Manufacturing Quality Deviations
FDA (Drugs) · 2022-03-30